Opendata, web and dolomites


Continuous Blood Glucose Monitoring and automated therapeutic closed loop medical device for Intensive Care Units

Total Cost €


EC-Contrib. €






 ContiTRACE project word cloud

Explore the words cloud of the ContiTRACE project. It provides you a very rough idea of what is the project "ContiTRACE" about.

careful    risk    caregivers    model    pharma    glucose    icu    doctors    proves    max    limited    death    automatically    lifecycle    estimates    investment    samples    medical    40    twofold    care    savings    profil    calibrating    hospital    material    intensive    monitoring    distributors    technique    manufacturers    standardized    inefficient    keep    levels    sasse    human    discomfort    mortality    glycaemic    x10    sell    5th    healthcare    2026    accesses    diagnostica    optimize    consumables    sensors    14    irregular    infuse    units    sanofi    patented    roche    blood    time    bgm    regulatory    patient    insulin    decrease    intermittent    costly    continuous    17    newcomers    safety    safe    elektronik    big    2022    infusion    headcounts    fluctuations    15    adjustments    physiological    self    public    companies    300    trace    profits    automated    patients    manual    workload    device    economic    ai    informed    pfizer    made    return    body    commercial    days    contitrace    increments    decisions    players    private    forecast    business    50    penetrate    aventis    minutes    powered    offline    comorbidities    invasive    icus    minimising    company   

Project "ContiTRACE" data sheet

The following table provides information about the project.


Organization address
postcode: 38106
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TRACE ANALYTICS GMBH DE (BRAUNSCHWEIG) coordinator 50˙000.00


 Project objective

Intensive Care Units (ICUs) require careful monitoring of blood glucose levels and insulin infusion to keep patients within safe physiological levels. Fluctuations of blood glucose are directly related to an increased risk of death and comorbidities. However, blood glucose monitoring (BGM) is still made by intermittent and manual offline analysis of blood samples. This technique proves inefficient (need 17% caregivers time), costly (€300 per patient) and increments mortality in hospital ICUs by 40% due to irregular glucose level adjustments upon measurements. After 15 years of experience in developing glucose monitoring sensors, we at TRACE are taking on our next big step to penetrate the medical device sector with ContiTRACE: an AI powered automated non-invasive medical device for continuous BGM. Our patented ContiTRACE is able to measure glycaemic levels every 2 minutes (automatically) and automatically infuse insulin when needed. It is also capable of self-calibrating and has standardized body accesses, enhancing safety and minimising discomfort for the ICU patient. This will allow 1) caregivers to decrease their workload, 2) doctors to take informed decisions and 3) the healthcare system to optimize their limited human, economic and material resources by providing savings of more than 50% of BGM related cost. Our business model is twofold. We will sell the medical device (5 years lifecycle), and the consumables (max. 4 days duration per set) to private and public hospital ICUs. Our draft forecast (2022-2026) estimates profits of 14.4 M€ with a Return on Investment of 10.7 by the 5th commercial year allowing us to increase x10 our company headcounts in five commercial years. Although newcomers to the medical sector we have the support of key players among regulatory companies (Profil), manufacturers (Sasse Elektronik), pharma companies (Sanofi-Aventis, Pfizer and Roche) and distributors (Care Diagnostica) to take on the BGM challenge.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CONTITRACE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CONTITRACE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TANDEM (2019)

Tuneable Acoustic Noise DampEning Material

Read More  

CoLumbo (2019)


Read More  

ARON (2020)

Assay-Ready Organ Network

Read More